Want to see AU:RGT full AI Analyst Report?
Argent Biopharma (RGT) AI Stock Analysis
Argent Biopharma
(ASX:RGT)
The score is driven primarily by very weak financial performance (sharp revenue contraction, negative gross profit, persistent large losses, negative equity, and ongoing cash burn). Technical indicators also lean bearish with the price below key moving averages and negative MACD. Valuation is constrained by a negative P/E and lack of dividend yield data.
Argent Biopharma (RGT) vs. iShares MSCI Australia ETF (EWA)
- Market Cap
- AUD 2.95M
- Dividend Yield
- ―
- Average Volume (3M)
- 175.32K
- Price to Earnings (P/E)
- -0.2
- Beta (1Y)
- -1.31
- Revenue Growth
- 17.56%
- EPS Growth
- 75.11%
- Country
- Australia
- Employees
- 5
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Argent Biopharma Business Overview & Revenue Model
Company Description
Argent BioPharma Limited, an Australian-headquartered biopharmaceutical firm founded in 2014, operates as a clinical-stage entity focused on developing innovative nano-engineered therapeutics. The company's core mission involves crafting treatments d...
Argent Biopharma Financial Statement Overview
Summary
Financial performance is severely weak: revenue fell sharply in 2026 (~-63% YoY), gross profit turned negative, losses are very large relative to sales (net margin ~-48%), equity is negative (2023–2026), and cash flow remains consistently negative with ongoing free-cash-flow burn.
Income Statement
8Very NegativeBalance Sheet
12Very NegativeCash Flow
10Very Negative| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 428.33K | 161.19K | 583.45K | 891.08K | 3.39M | 4.73M |
| Gross Profit | -213.34K | -204.21K | 446.32K | 203.70K | 1.45M | 1.81M |
| EBITDA | -11.92M | -7.23M | -17.00M | -15.77M | -20.04M | -16.54M |
| Net Income | -6.79M | -7.71M | -17.84M | -17.53M | -20.82M | -16.77M |
Balance Sheet | ||||||
| Total Assets | 1.29M | 1.29M | 2.47M | 10.79M | 9.88M | 23.55M |
| Cash, Cash Equivalents and Short-Term Investments | 141.46K | 141.46K | 1.02M | 702.87K | 239.82K | 1.79M |
| Total Debt | 9.59M | 9.59M | 8.29M | 1.04M | 575.14K | 4.39M |
| Total Liabilities | 10.74M | 10.74M | 11.10M | 16.61M | 18.02M | 13.66M |
| Stockholders Equity | -9.45M | -9.45M | -8.63M | -5.15M | -7.51M | 11.23M |
Cash Flow | ||||||
| Free Cash Flow | -9.63M | -4.03M | -9.28M | -14.80M | -12.18M | -14.85M |
| Operating Cash Flow | -9.62M | -4.03M | -9.28M | -14.66M | -11.99M | -12.16M |
| Investing Cash Flow | 209.95K | -721 | 208.83K | -140.12K | 606.20K | -1.11M |
| Financing Cash Flow | 9.78M | 3.14M | 9.39M | 15.27M | 9.73M | 9.74M |
Argent Biopharma Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:RGT, the sentiment is Negative. The current price of 0.03 is below the 20-day moving average (MA) of 0.03, below the 50-day MA of 0.03, and below the 200-day MA of 0.04, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 41.71 is Neutral, neither overbought nor oversold. The STOCH value of 16.06 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:RGT.
Argent Biopharma Peers Comparison
Overall Rating
AU:CAN53Neutral
AU:VIT44Neutral
AU:EXL43.2Neutral
AU:LGP41Neutral- AU:RGT40Underperform
AU:PKP39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| AU:CAN | 53Neutral | AUD 8.30M | 0.30 | 64.70% | ― | -24.22% | ― |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| AU:VIT | 44Neutral | AUD 13.25M | -2.98 | -9.80% | ― | 5.74% | -222.22% |
| AU:EXL | 43Neutral | AUD 2.72M | -0.59 | -50.35% | ― | -4.87% | -9.78% |
| AU:LGP | 41Neutral | AUD 49.68M | -13.04 | -1.67% | ― | 15.21% | -141.82% |
| AU:RGT | 40Underperform | AUD 2.95M | -0.23 | 102.60% | ― | 17.56% | 75.11% |
| AU:PKP | 39Underperform | AUD 21.43M | -5.07 | 4388.00% | ― | -19.73% | 50.34% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:RGT | Argent Biopharma Ltd | 0.03 | -0.06 | -71.59% | |
| AU:EXL | Elixinol Wellness Ltd | 0.01 | 0.00 | 25.00% | |
| AU:CAN | Cann Group Ltd. | 0.01 | -0.00 | -9.09% | |
| AU:LGP | Little Green Pharma Ltd. | 0.06 | -0.07 | -53.85% | |
| AU:PKP | Althea Group Holdings Ltd. | 0.02 | -0.01 | -23.81% | |
| AU:VIT | Cronos Australia Ltd. | 0.02 | -0.04 | -67.74% |
Argent Biopharma Corporate Events
Argent BioPharma Licenses Non-Core Cannabis Genetics in Global Deal with Thai Phytomed
Argent BioPharma has signed a 10-year exclusive worldwide licensing agreement with Thai Phytomed International for the commercial development of four proprietary cannabis genotypes. Under the deal, Argent retains ownership of the genetics and related...
Argent Biopharma sharpens immune focus and monetises CannEpil with new licensing deals
Argent Biopharma has sharpened its strategic focus around immune modulation and inflammation, elevating RGT-CA91980 as its lead programme and integrating licensed NLC antiviral products with its CimetrA® franchise. The company is prioritising co...
Argent BioPharma Sets November Date for Annual General Meeting
Argent BioPharma has dispatched documentation for its Annual General Meeting, scheduled for 10:00AM AWST on 20 November 2026 at its Subiaco, Western Australia premises, including the notice of meeting and proxy materials for shareholders. The release...
Argent BioPharma Sets AGM Date and Director Nomination Deadline
Argent BioPharma has scheduled its Annual General Meeting for Friday, 20 November 2026, and set a deadline of 5:00 p.m. WST on 21 October 2026 for shareholders to submit nominations for individuals seeking election to the board of directors. The anno...
Argent BioPharma Refines Immune Modulation Strategy Around Inflammation and Healthy Ageing
Argent BioPharma is sharpening its focus on immune modulation and inflammatory disease, building a portfolio that combines in-house pharmaceutical development, advanced drug delivery and early-stage biologic research with licensed commercial products...
Argent Biopharma Seeks ASX Quotation for 1.25 Million New Shares
Argent Biopharma Limited has applied for quotation of 1,250,000 new ordinary fully paid shares on the ASX, expanding its listed security base under the code RGT. The issuance, dated October 2, 2026, reflects the conversion of existing options or othe...
Argent Biopharma Plans Issue of 2 Million Performance Rights
Argent Biopharma Limited has notified the Australian Securities Exchange of its intention to issue up to 2,000,000 performance rights under a proposed placement or similar type of security issue. The performance rights, to be issued under the code RG...
Argent Biopharma Cancels Over 5.5 Million Convertible Notes
Argent Biopharma Limited has updated the market on changes to its capital structure, notifying the cessation of a series of convertible notes listed under the ASX code RGTAAA. The company reported that 5,502,532 of these convertible securities have b...
Argent BioPharma Narrows Annual Loss After Restructuring and Cost Controls
Argent BioPharma reported revenue of $161,187 for the year ended 30 June 2026, an 11% decline from the prior year, while its net loss narrowed markedly to $7.7 million from $17.8 million as tighter expenditure discipline took hold. The board did not...
Argent Biopharma Details Governance Compliance in ASX Filing
Argent Biopharma has lodged its Appendix 4G and confirmed that its corporate governance statement for the year ended 30 June 2026 is available on its website, in line with ASX Listing Rules. The filing, approved by the board as of 31 August 2026, out...
Argent BioPharma Secures FDA-CVM INAD for CannEpil Veterinary Cancer-Pain Program
Argent BioPharma’s CannEpil platform is being extended into veterinary healthcare through a global licensing arrangement with Endovia Health Sciences, with Lupvindol Biosciences leading scientific and regulatory development in the U.S. The init...
Argent Biopharma Plans Options and Convertible Notes Issue to Bolster Funding
Argent Biopharma Limited has lodged an Appendix 3B with the ASX detailing a proposed issue of new securities as part of a placement or similar capital raising. The company plans to issue up to 2,010,724 unlisted options exercisable at A$0.09325 with...
Argent BioPharma Advances CannEpil into U.S. Veterinary Market with New Development Program
Argent BioPharma’s licensing partner Splash Beverage Group has launched a U.S. veterinary pharmaceutical development program for CannEpil®, in collaboration with Lupvindol Biosciences, marking the product’s expansion into animal heal...
Argent Biopharma Options Expire Unexercised, Simplifying Capital Structure
Argent Biopharma has announced the cessation of 181,422 options with an exercise price of $3.00, which expired on 31 July 2026 without being exercised or converted. The expiry reduces the company’s pool of outstanding convertible securities, sl...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 06, 2026